Intended use:
The RIDASCREEN® Clostridium perfringens Enterotoxin test is an enzyme immunoassay for the qualitative determination of Clostridium perfringens Enterotoxin in human stool samples.
General information:
Clostridium perfringens bacteria are regularly found among the flora of the large intestine in humans. Certain strains of C. perfringens produce a number of toxins, among which the enterotoxin (a polypeptide 35 kDa in size) is of pathogenic significance for humans. With the consumption of improperly stored foods, and then pre-cooked foods in particular, C. perfringens may be imbibed in large amounts. They, in turn, form large amounts of C. perfringens enterotoxins (CPE) and these are the cause of intestinal diseases with diarrhea and stomach cramps. In addition to food poisoning, C. perfringens causes about 10% of all cases of antibiotic-associated diarrhea (AAD) as well as 5–20% of the cases of sporadic diarrhea (SPOR) that are not caused by food poisoning.
The RIDASCREEN® Clostridium perfringens Enterotoxin is available parallel to the RIDASCREEN® Clostridium difficile Toxin A/B ELISA, providing a significant identification system for clarification of the causes of antibiotic-associated diarrhea and sporadic diarrhea. Allowing fast and reliable diagnosis, this tool is a valuable aid in the treatment decision process.
Accessories:
Single Components:
- RIDASCREEN® Control – (Negative Control)
- RIDASCREEN® Diluent 1
- RIDASCREEN® Substrate
- RIDASCREEN® Stop
- RIDASCREEN® Wash buffer 10x
| Art. No. | C0601 |
|---|---|
| Test format | Microtiter plate with 96 wells (12 strips with 8 removable wells each) |
| Incubation time | 105 min |
| Detection limit | 0.04 ng/ml Enterotoxin |
Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com.
